| B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | CIDp Index | Primary diagnosis | PBMC vials | PBMC cells per vial | Serum vials | Serum volume per vial | Gender | Age | Ethnicity | Height (cm) | Weight (kg) | Detailed diagnosis (including stage) | Date of diagnosis (Psoriatic Arthritis) | Lesion areas, severity, activity | Current therapy | Concomitant disorders | Smoking | Alcohol | |
2 | CIDp780016268 | Psoriatic arthritis | 2 | 1.0 ml | F | 66 | Caucasian (White) | 150 | 63 | Systemic form of psoriatic arthritis | 2014 | Ankle joints, hand joints, activity-2, joint functional impairment -2. Renal amyloidosis. | Methotrexate | Essential hypertension-2, Diabetes-2, Ischemic heart disease, Atherosclerotic cardiosclerosis. | No | No | |||
3 | CIDp780016269 | Psoriatic arthritis | 2 | 1.0 ml | F | 51 | Caucasian (White) | 162 | 94 | Polyarticular form of psoriatic arthritis, without systemic manifestations | 2013 | Large joints, activity 2, joint functional impairment -1 | Methotrexate | Degenerative-dystrophic diseases of the spine, Essential hypertension-2, Dyslipidemia . | No | No | |||
4 | CIDp780016270 | Psoriatic arthritis | 1 | 1.0 ml | M | 66 | Caucasian (White) | 174 | 95 | Polyarticular form of psoriatic arthritis | 2012 | Shoulder joints, knee joint, small hand joints. Activity-2, joint functional impairment -2 | Methotrexate | Ischemic heart disease, Postinfarction cardiosclerosis, Essential hypertension-2, Cerebrovascular disease. | No | No | |||
5 | CIDp780016271 | Psoriatic arthritis | 3 | 1.0 ml | F | 56 | Caucasian (White) | 162 | 65 | Polyarticular form of psoriatic arthritis | 2014 | Ankle joints, hand joints. activity-2 joint functional impairment -1 | No | Chronic cholecystitis, Intestine dyskinesia. | No | No | |||
6 | CIDp780016272 | Psoriatic arthritis | 2 | 1.0 ml | M | 33 | Caucasian (White) | 180 | 70 | Psoriatic arthritis stage 2, without systemic manifestations | 2011 | All joints are affected diffusely , activity-1, joint functional impairment 1 | Methotrexate | No | 0.5 packs per day | No | |||
7 | CIDp780016273 | Psoriatic arthritis | 2 | 1.0 ml | M | 56 | Caucasian (White) | 160 | 68 | Psoriatic arthritis stage 2, without systemic manifestations | 2014 | Large joints, activity 1, joint functional impairment -2 | No | Essential hypertension-2, Phlebeurysm. | 1 pack per day | Yes (minor volumes) | |||
8 | |||||||||||||||||||
9 | CIDp780016274 | Psoriatic arthritis | 3 | 1.0 ml | F | 47 | Caucasian (White) | 173 | 70 | Spondiloarthritic form of psoriatic arthritis, without systemic manifestations | 2015 | Shoulder joints, knee joints, ankle joints. activity-2, joint functional impairment -2 | Non-steroidal anti-inflammatory drugs | Degenerative-dystrophic diseases of the spine, Cholelithiasis. | No | Yes (moderate) | |||
10 | CIDp780016275 | Psoriatic arthritis | 2 | 1.0 ml | M | 56 | Caucasian (White) | 185 | 78 | Psoriatic arthritis stage 2, without systemic manifestations | 2012 | Spine, elbow joints, small hand joints. Activity-2, joint functional impairment 2 | Methotrexate, Glucocorticoids | Vegetative-vascular dystonia. | No | No | |||
11 | CIDp780016276 | Psoriatic arthritis | 3 | 1.0 ml | F | 49 | Caucasian (White) | 164 | 77 | Psoriatic arthritis stage 2, without systemic manifestations | 2013 | All the joints, spine. Activity-2, joint functional impairment 3 | Methotrexate | Cerebrovascular disease, Chronic cholecystitis. | No | No |